Desitin Arzneimittel GmbH has signed an exclusive License Agreement to commercialize an orphan drug being developed by AFT Pharmaceuticals, a specialist pharmaceutical company based in Auckland, New Zealand, to treat facial angiofibromas, a symptom of Tuberous Sclerosis Complex (TSC). TSC is a genetic disease, estimated to affect 50,000 patients across Europe(1). Around 75% of those TSC patients suffer from facial angiofibromas(1), which can cause pain, bleeding, infections and in adverse cases impair breathing and vision(1).
Desitin has in-licensed the exclusive rights on this innovative orphan drug for distribution in Europe, the United Kingdom, Switzerland and Norway. This deal will enable Desitin to expand its presence throughout Europe.
Desitin Co-CEO Philipp Bloching, MD says: “We are convinced by this breakthrough development to treat patients suffering from facial angiofibromas, a symptom of Tuberous Slerosis Complex. We are excited to further expand Desitin´s portfolio in CNS and rare diseases.”
AFT Pharmaceutical Managing Director Dr Hartley Atkinson says: “We are delighted to partner with Desitin, which has excellent coverage and expertise in this therapeutic area across Europe.”
(1) Ebrahimi-Fakhari, D., et al. (2017). “Dermatological manifestations of tuberous sclerosis complex (TSC).” J Dtsch Dermatol Ges 15(7): 695-700.
Desitin is a privately held, medium-sized, fully integrated pharmaceutical company based in Hamburg/Germany and operating in Europe. The focus is on the CNS market and on rare diseases. Desitin holds market leading positions in particular in epilepsy and Parkinson´s disease. The company has been active for more than 100 years in the production, distribution and promotion of pharmaceutical products to specialists and hospitals. The sources of growth are own developments as well as in-licensed products from large multinational as well as from small local companies.
AFT is a growing multinational pharmaceutical business with a broad range of products, both developed in-house and in-licensed from third parties. AFT’s products cover all major pharmaceutical distribution channels: over-the-counter, prescription and hospital. Historically, AFT’s home markets have been Australia, New Zealand and South-East Asia. However, the company is out-licensing its own products to licensees and distributors to sell in an increasing number of countries around the world. The company’s intensive research and development program forms the basis of its international sales strategy.